Trial Profile
A phase II study of lenalidomide and prednisolone as post-ASCT maintenance therapy for patients with Multiple Myeloma incorporating residual disease monitoring
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Prednisolone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms LEOPARD
- Sponsors Celgene Corporation
- 08 Dec 2020 Results assessing mass cytometry (CyTOF) based immune profiling in patients with newly diagnosed Multiple Myeloma patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 23 Jun 2011 New trial record